| HOME >> BIOLOGY >> TECHNOLOGY |
Notes payable, less current portion - 119,000
Capital lease obligation, less current portion 22,000 30,000
Deferred license revenue - 4,000
Commitments and contingencies
STOCKHOLDERS' EQUITY:
Preferred stock - $.001 par value; authorized
5,000,000 shares; non-voting; nil shares
outstanding - -
Common stock - $.001 par value; authorized
325,000,000 shares; outstanding - 226,210,617
and 196,112,201, respectively 226,000 196,000
Additional paid-in-capital 246,205,000 224,453,000
Accumulated deficit (230,836,000) (207,660,000)
Total stockholders' equity 15,595,000 16,989,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $23,057,000 $22,997,000
-continued-
PEREGRINE PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2008
2008 2007 2006
REVENUES:
Contract manufacturing
revenue $5,897,000 $3,492,000 $3,005,000
License revenue 196,000 216,000 188,000
Total revenues 6,093,000 3,708,000 3,193,000
COSTS AND EXPENSES:
Cost of contract
manufacturing 4,804,000 3,296,000 3,297,000
Research and development 18,279,000 15,876,000 12,415,000
Selling, general and
administrative 7,150,000 6,446,000 6,564,000
Total costs and
expenses 30,233,000 25,618,000 22,276,000
LOSS FROM OPERATIONS (24,140,000) (21,910,000) (19,08
'/>"/>
| SOURCE Peregrine Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |